Drug discovery for hyperuricemia

Expert Opinion on Drug Discovery

Volumn 2, Issue 9, 2007, Pages 1251-1261

  Anzait, Naohiko ^a   Endou, Hitoshi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CFEX; Hyperuricemia; PDZK1; SMCT; URAT1; Urate

Indexed keywords

ALLOPURINOL; ANTILIPEMIC AGENT; BENZBROMARONE; CARRIER PROTEIN; CHLORIDE; DIURETIC AGENT; FEBUXOSTAT; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTIC ACID; LOSARTAN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PDZ PROTEIN; PHENYLBUTAZONE; PROBENECID; PYRAZINOIC ACID; RASBURICASE; SULFINPYRAZONE; UNCLASSIFIED DRUG; URATE; URATE TRANSPORTER 1; URIC ACID; URICOSURIC AGENT;

ANION EXCHANGE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; GENE MUTATION; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; LIVER DISEASE; LIVER FUNCTION; LIVER TOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PURINE METABOLISM; PURINE SYNTHESIS; REVIEW; STEVENS JOHNSON SYNDROME; URINARY EXCRETION; UROLITHIASIS;

EID: 34848852618     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.9.1251     Document Type: Review

References (70)

1. WORTMANN RL, KELLY W: Gout and hyperuricemia. In: Kelly's Textbook of Rheumatology Crystal-associated Synovitis. Ruddy S, Harris ED Jr, Sledge CB (Eds), WB Saunders, Philadelphia (2001):1339-1376.
2. EMMERSON BT: Hyperuricemia, gout, and the kidney. In: Diseases of the Kidney. Schrier RW, Gottschalk CW (Eds), Little, Brown and Company, Boston (1997):2175-2199.
3. TERKELTAUB RA: Clinical practice. Gout. N. Engl. J. Med. (2003) 349:1647-1655.
4. EMMERSON BT: The management of gout. N. Engl. J. Med. (1996) 334:445-451.
5. BIEBER JD, TERKELTAUB RA: Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. (2004) 50:2400-2414.
6. TERKELTAUB RA, BUSHINSKY DA, BECKER MA: Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthiritis Res. Ther. (2006) 8(Suppl. 1):S4.
7. LEE SJ, TERKELTAUB RA: New developments in clinically relevant mechanisms and treatment of hyperuricemia. Curr. Rheumatol. Rep. (2006) 8:224-230.
8. HOSKISON TK, WORTMANN RL: Advances in the management of gout and hyperuricaemia. Scand. J. Rheumatol. (2006) 35:251-260.
9. PASCUAL E, SIVERA F: Therapeutic advances in gout. Curr. Opin. Rheumatol. (2007) 19:122-127.
10. SICA DA, SCHOOLWERTH AC: Real handling of organic anions and cations: excretion of uric acid. In: The Kidney. Brenner BM (Ed.), WB Saunders, Philadelphia (2000):680-700.
11. WU XW, MUZNY DM, LEE CC et al.: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J. Mol. Evol. (1992) 34:78-84.
12. WORTMANN RL: Disorders of purine and pyrimidine metabolism. In: Harrison's Principles of Internal Medicine. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (Eds), McGraw-Hill, New York (2005):2308-2313.
13. COMMITTEE FOR THE PREPARATION OF THERAPEUTIC GUIDELINES: Guidelines for the management of hyperuricemia and gout (in Japanese). Gout Nucleic Acid Metab. (2002) 26(Suppl. 1):1-79.
14. SEEGMILLER JE, ROSENBLOOM FM, KELLEY WN: Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science (1967) 155:1682-1694.
15. KELLEY WN, ROSENBLOOM FM, HENDERSON JF et al.: A specific enzyme defect in gout associated with overproduction of uric acid. Proc. Natl. Acad. Sci. USA (1967) 57:1735-1739.
16. BECKER MA, NOSAL JM, SWITZER RL et al.: Point mutations in PRPS1, the gene encoding the PPRP sythetase (PRS) 1 isoform, underlie X-liked PRS superactivity associated with purine nucleotide inhibitor-resistance. Adv. Exp. Med. Biol. (1994) 370:707-710.
17. ENOMOTO A, KIMURA H, CHAIROUNGDUA A et al.: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature (2002) 417:447-452.
18. SIMMONDS HA, MCBRIDE MB, HATFIELD PJ et al.: Polynesian women are also at risk for hyperuricemia and gout because of a genetic defect in renal urate handling. Br. J. Rheumatol. (1994) 33:932-937.
19. MCBRIDE MB, RIGDEN S, HAYCOCK GB et al.: Presymptomatic detection of familial juvenile hyperuricaemic ephropathy in children. Pediatr. Nephrol. (1998) 12:357-364.
20. KAMATANI N, MORITANI M, YAMANAKA H et al.: Localization of a gene for familial juvenile hyperuricemic nephropathy causing underexcretion-type gout to 16p12 by genome-wide linkage analysis of a large family. Arthritis Rheum. (2000) 43:925-929.
21. HART TC, GORRY MC, HART PS et al.: Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J. Med. Genet. (2002) 39:882-892.
22. TURNER JJ, STACEY JM, HARDING B et al.: Uromodulin mutations cause familial juvenile hyperuricemic nephropathy. J. Clin. Endocriol. Metab. (2003) 88:1398-1401.
23. MAESAKA JK, FISHBANE S: Regulation of renal urate excretion: a critical review. Am. J. Kidney Dis. (1998) 32:917-933.
24. ABRAMSON RG, LIPKOWITZ MS: Evolution of the uric acid transport mechanisms in vertebrate kidney. In: Basic Principles in Transport, Comp. Physiol. (Volume 3). Kinne RKH (Ed.), Karger, Basel (1990):115-153.
25. ANZAI N, ENOMOTO A, ENDOU H: Renal urate handling-clinical relevance of recent advances. Curr. Rheumatol. Rep. (2005) 7:227-234.
26. HEDIGER MA, JOHNSON RJ, MIYAZAKI H, ENDOU H: Molecular physiology of urate transport. Physiology (Bethesda) (2005) 20:125-133.
27. ANZAI N, KANAI Y, ENDOU H: New insights into renal transport of urate. Curr. Opin. Rheumatol. (2007) 19:151-157.
28. MOUNT DB, KWON CY, ZANDI-NEJAD K: Renal urate transport. Rheum. Dis. Clin. North Am. (2006) 32:313-331.
29. NAKASHIMA M, UEMATSU T, KOSUGE K, KANAMARU M: Pilot study of the uricosuric effects of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. (1992) 42:333-335.
30. ROCH-RAMEL F, WERNER D, GUISAN B: Urate transport in brush-border membrane of human kidney. Am. J. Physiol. (1994) 266:F797-F805.
31. STEELE TH: Urate secretion in man: the pyrazinamide suppression test. Ann. Intern. Med. (1976) 79:734-737.
32. CULLEN JH, LEVINE M, FIORE JM: Studies of hyperuricemia produced by pyrazinamide. Am. J. Med. (1957) 23:587-595.
33. ICHIDA K, HOSOYAMADA M, HISATOME I et al.: Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J. Am. Soc. Nephrol. (2004) 15:164-173.
34. KOMODA F, SEKINE T, INATOMI J et al.: The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia. Pediatr. Nephrol. (2004) 19:728-733.
35. KAHN AM, WEINMAN EJ: Urate transport in the proximal tubule: in vivo and vesicle studies. Am. J. Physiol. (1985) 249:F789-F798.
36. GOPAL E, FEI YJ, SUGAWARA M et al.: Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate. J. Biol. Chem. (2004) 279:44522-44532.
37. SRINIVAS SR, GOPAL E, ZHUANG L et al.: Cloning and functional identification of slc5a12 as a sodium-coupled low-affinity transporter for monocarboxylates (SMCT2). Biochem. J. (2005) 392:655-664.
38. ZANDI-NEJAD K, PLATA C, ENCK AH et al.: Slc5a8 functions as a sodium-dependent pyrazionate and nicotinate cotransporter; Implications for renal urate transport. J. Am. Soc. Nephrol. (2004) 15:A89 (Abstract).
39. THANGARAJU M, ANANTH S, MARTIN PM et al.: c/ebpdelta null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J. Biol. Chem. (2006) 281:26769-26773.
40. ARONSON PS, GIEBISCH G: Mechanisms of chloride transport in the proximal tubule. Am. J. Physiol. (1997) 273:F179-F192.
41. KNAUF F, YANG CL, THOMSON RB, MENTONE SA, GIEBISCH G, ARONSON PS: Identification of a chloride-formate exchanger expressed on the brush border membrane of renal proximal tubule cells. Proc. Natl. Acad. Sci. USA (2001) 98:9425-9430.
42. RUSSEL FG, MASEREEUW R, VAN AUBEL RA: Molecular aspects of renal anionic drug transport. Ann. Rev. Physiol. (2002) 64:563-594.
43. ANZAI N, JUTABHA P, KANAI Y, ENDOU H: Integrated physiology of proximal tubular organic anion transport. Curr. Opin. Nephrol. Hypertens. (2005) 14:472-479.
44. ANZAI N, MIYAZAKI H, NOSHIRO R et al.: The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C-terminal. J. Biol. Chem. (2004) 279:45942-45950.
45. ANZAI N, MIYAZAKI H, HE X et al.: Identification of the multivalent PDZ domain protein PDZK1 as a binding partner of sodium-coupled monocarboxylate cotransporter 1 (SMCT1). J. Am. Soc. Nephrol. (2006) 17:A753 (Abstract).
46. THOMSON RB, WANG T, THOMSON BR et al.: Role of PDZK1 in membrane expression of renal brush border ion exchangers. Proc. Natl. Acad. Sci. USA (2005) 102:13331-13336.
47. ANZAI N, KANAI Y, ENDOU H: Organic anion transporter family: current knowledge. J. Pharmacol. Sci. (2006) 100:411-426.
48. PEREZ-RUIZ F, CALABOZO M, PIJOAN JI et al.: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. (2002) 47:356-360.
49. SHOJI A, YAMANAKA H, KAMATANI N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. (2004) 51:321-325.
50. ZHANG W, DOHERTY M, BARDIN T et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann. Rheum. Dis. (2006) 65:1312-1324.
51. MIKULS TR, MACLEAN CH, OLIVIERI J et al.: Quality of care indicators for gout management. Arthritis Rheum. (2004) 50:937-943.
52. YAMANAKA H, KAMATANI N, KASHIWAZAKI S: Comparative study concerning the effects of allopurinol and benzbromarone based on the uric acid metabolism (in Japanese). Hyperuricemia and Gout (1994) 2:103-111.
53. YU TF, GUTMAN AB: Uric acid urolithiasis in gout: predisposing factors. Ann. Intern. Med. (1967) 67:1133-1148.
54. GUTMAN AB, YU TF: Protracted uricosuirc therapy in tophaceous gout. Lancet (1955) 2:1258-1260.
55. STAMP LK, O'DONNELL JL, CHAPMAN PT: Emerging therapies in the long-term management of hyperuricaemia and gout. Intern. Med. J. (2007) 37:258-266.
56. ENROTH C, EGER BT, OKAMOTO K et al.: Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. Proc. Natl. Acad. Sci. USA (2000) 97:10723-10728.
57. EGER BT, OKAMOTO K, ENROTH C et al.: Purification, crystallization and preliminary X-ray diffraction studies of xanthine dehydrogenase and xanthine oxidase isolated from bovine milk. Acta Cystallogr. D. Biol. Crystallogr. (2000) 56:1656-1658.
58. KUWABARA Y, NISHINO T, OKAMOTO K et al.: Unique amino acids cluster for switching from the dehydrogenase to oxidase form of xanthine oxidoreductase. Proc. Natl. Acad. Sci. USA (2003) 100:8170-8175.
59. HANDE KR, NOONE RM, STONE WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am. J. Med. (1984) 76:47-56.
60. HUNG S, CHUNG W, LIOU L et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA (2005) 102:4134-4139.
61. YOSHIMURA R, FUJIMORI A, SAITO H et al.: Analysis of allopurinol metabolism in urate translocation mechanism disorder (in Japanese). Purine Pyrimidine Metab. (1994) 18:37.
62. BECKER MA, SCHUMACHER HR Jr, WORTMANN RL et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. (2005) 353:2450-2461.
63. OKAMOTO K, EGER BT, NISHINO T, KONDO S, PAI EF, NISHINO T: An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J. Biol. Chem. (2003) 278:1848-1855.
64. HORIUCHI H, OTA M, NISHIMURA S et al.: Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci. (2000) 66:2051-2070.
65. PUI CH, JEHA S, IRWIN D, CAMITTA B: Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia (2001) 15:1505-1509.
66. BOMALASKI JS, CLARK MA: Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr. Rheumatol. Rep. (2004) 6:240-247.
67. BASTOW MD, DURRINGTON PN, ISHOLA M: Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism (1988) 37:217-220.
68. KAKAFIKA A, TSIMIHODIMOS V, ELISAF M: Effect of atorvastatin on serum uric acid levels. Atherosclerosis (2001) 158:255.
69. IWANAGA T, SATO M, MAEDA T et al.: Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J. Pharmacol. Exp. Ther. (2007) 320:211-217.
70. DEV KK: Making protein interactions druggable: targeting PDZ domains. Nat. Rev. Drug Discov. (2004) 3:1047-1056.